CEL-SCI Corporation(NYSE MKT:CVM) 
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antig...
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 5.71
H 7.21
L 5.41
C 6.61
V 1,677,268
10EMA 6.61
20EMA 6.61
60EMA 6.61
120EMA 6.61
250EMA 6.61